NCI and Patient Advocates Tackle The Drug Shortage Issue

Max Wallace, CEO of Accelerate Brain Cancer Cure, represented the brain tumor community at a patient advocacy meeting hosted by the National Cancer Institute last month.

The National Cancer Institute Director's Consumer Liaison Group (DCLG) held its first meeting of the new year February 29–March 1 in Bethesda, MD. The meeting included presentations on understanding cancer drug shortages and the role of patient advocate groups in addressing the issue.  NCI Director Harold Varmus led the discussions and Max Wallace, CEO of ABC2, represented the brain tumor community at the meeting.

At the meeting, Bruce A. Chabner, M.D. of Massachusetts General Hospital discussed the challenges facing the cancer community, "The shortages primarily affect injectable generic drugs and have forced physicians to prioritize patients and improvise standard drug regimens," said Chabner.  "The origins of the shortages are multifactorial, but simply stated, the problem for cancer treatment stems from a confluence of factors: consolidation of generic-drug production in the hands of few manufacturers, who in turn have experienced both increased demand for drugs and production problems."

The 15 members of the DCLG provide informed, non-scientific perspectives to the NCI director on promoting research outcomes that are in the best interest of cancer patients. Specifically, DCLG members focus on identifying new approaches, promoting innovation, recognizing unforeseen risks or barriers, and identifying unintended consequences that could result from NCI decisions or actions.  Max Wallace has been a member of the DCLG since 2010.

Main Image Credit: 
Share |
October 21, 2014 09:33 PM
ABC2 CEO Max Wallace chaired the gathering of NCI experts and cancer advocates.
October 15, 2014 12:44 PM
Principal Investigators, based in the state of Florida, are invited to apply. Proposal deadline: December 15, 2014. 
October 14, 2014 12:50 PM
ABC2 funds project between UC San Diego Health System and Regulus Therapeutics Inc.

Join us in our fight for a cure!

Twitter